THE COUNCIL OF THE QUEENSLAND INSTITUTE OF MEDICAL RESEARCH

Atara Biotherapeutics Approaches Critical FDA Decision for Tab-cel as Company Implements Strategic Restructuring

- Atara Biotherapeutics faces a pivotal FDA decision on January 10, 2026, for Tab-cel, a potential first-in-class treatment for EBV+ PTLD with no currently approved alternatives in the United States. - The company has implemented its third workforce reduction this year, cutting 29% of remaining staff to just 15 employees while reducing operating expenses by at least 60% through partnership with Pierre Fabre Laboratories. - A successful FDA approval would trigger a $40 million milestone payment from Pierre Fabre and position Atara to receive double-digit tiered royalties on net sales. - Despite financial challenges with $13.7 million in cash as of September 2025, the company's stock has gained 8.4% over two weeks, trading at $16.83 with increased volume ahead of the regulatory decision.